Compare 10X Genomics Inc (TXG) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? 10X Genomics Inc trades at $46.82 (market cap $5.48B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. The key difference: 10X Genomics Inc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| TXG | VCIT | |
|---|---|---|
Market Cap | $5.48B | — |
Sector | Health | Fixed Income |
52-Week High | $45.80 | $84.82 |
52-Week Low | $11.34 | $81.45 |
Enterprise Value | $5.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VCIT trades at $81.71, down 0.28% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts of $0.33-$0.34, reflecting its income-focused strategy. News coverage highlights VCIT's competitive expense ratio of 0.03% and yield advantages over peers like VGIT and IEI, though technical indicators suggest near-term pressure with support clustered around $82.
The outlook balances VCIT's low-cost access to intermediate-term corporate bonds against interest rate sensitivity and economic cycle risks. Current bearish momentum warrants caution, but the fund's structural efficiency and yield appeal position it for income investors seeking diversified credit exposure amid fluctuating fixed-income conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
